April Jorge1, Natalie McCormick2, Na Lu2, Yufei Zheng3, John Esdaile3, Mary De Vera4, Hyon Choi1, J Antonio Aviña-Zubieta4. 1. Massachusetts General Hospital, Boston, Massachusetts. 2. Massachusetts General Hospital, Boston, Massachusetts, and Arthritis Research Canada, Richmond, British Columbia, Canada. 3. Arthritis Research Canada, Richmond, British Columbia, Canada. 4. Arthritis Research Canada, Richmond, and University of British Columbia, Vancouver, British Columbia, Canada.
Abstract
OBJECTIVE: Hydroxychloroquine (HCQ) has been associated with improved survival among patients with systemic lupus erythematosus (SLE) from tertiary referral centers. We aimed to determine the potential impact of HCQ use on the risk of mortality among SLE patients in the general population. METHODS: We conducted a nested case-control study within an incident SLE cohort from the entire population of British Columbia, Canada. Deceased patients were matched with up to 3 living controls by age, sex, and SLE disease duration. HCQ exposure was categorized by the time between the last HCQ prescription date covered (i.e., end of supply) and the index date (i.e., death date) as current (<30 days), recent (30-365 days), remote (>365 days), or never used. We used conditional logistic regression to assess the risk of all-cause mortality associated with current or recent HCQ exposure compared with remote HCQ users. RESULTS: Among 6,241 patients with incident SLE, we identified 290 deceased patients and 502 matched SLE controls. Adjusted odd ratios for all-cause mortality were 0.50 (95% confidence interval [95% CI] 0.30-0.82) for current users and 2.47 (95% CI 1.21-5.05) for recent users compared with remote users. Associations were similar in subgroups according to SLE duration (≤5 years versus >5 years). CONCLUSION: Our general population data support a substantial survival benefit associated with current HCQ use. Increased mortality among patients who had discontinued HCQ recently could be due to a sick stopper effect or the loss of actual HCQ benefits.
OBJECTIVE: Hydroxychloroquine (HCQ) has been associated with improved survival among patients with systemic lupus erythematosus (SLE) from tertiary referral centers. We aimed to determine the potential impact of HCQ use on the risk of mortality among SLE patients in the general population. METHODS: We conducted a nested case-control study within an incident SLE cohort from the entire population of British Columbia, Canada. Deceased patients were matched with up to 3 living controls by age, sex, and SLE disease duration. HCQ exposure was categorized by the time between the last HCQ prescription date covered (i.e., end of supply) and the index date (i.e., death date) as current (<30 days), recent (30-365 days), remote (>365 days), or never used. We used conditional logistic regression to assess the risk of all-cause mortality associated with current or recent HCQ exposure compared with remote HCQ users. RESULTS: Among 6,241 patients with incident SLE, we identified 290 deceased patients and 502 matched SLE controls. Adjusted odd ratios for all-cause mortality were 0.50 (95% confidence interval [95% CI] 0.30-0.82) for current users and 2.47 (95% CI 1.21-5.05) for recent users compared with remote users. Associations were similar in subgroups according to SLE duration (≤5 years versus >5 years). CONCLUSION: Our general population data support a substantial survival benefit associated with current HCQ use. Increased mortality among patients who had discontinued HCQ recently could be due to a sick stopper effect or the loss of actual HCQ benefits.
Authors: Daniel J Wallace; Vineet S Gudsoorkar; Michael H Weisman; Swamy R Venuturupalli Journal: Nat Rev Rheumatol Date: 2012-07-17 Impact factor: 20.543
Authors: Graciela S Alarcón; Gerald McGwin; Ana M Bertoli; Barri J Fessler; Jaime Calvo-Alén; Holly M Bastian; Luis M Vilá; John D Reveille Journal: Ann Rheum Dis Date: 2007-03-27 Impact factor: 19.103
Authors: J Antonio Aviña-Zubieta; Fergus To; Kateryna Vostretsova; Mary De Vera; Eric C Sayre; John M Esdaile Journal: Arthritis Care Res (Hoboken) Date: 2017-05-09 Impact factor: 4.794
Authors: David J Graham; David Campen; Rita Hui; Michele Spence; Craig Cheetham; Gerald Levy; Stanford Shoor; Wayne A Ray Journal: Lancet Date: 2005 Feb 5-11 Impact factor: 79.321
Authors: April Jorge; Na Lu; Hyon Choi; John M Esdaile; Diane Lacaille; J Antonio Avina-Zubieta Journal: Arthritis Care Res (Hoboken) Date: 2021-12-23 Impact factor: 5.178
Authors: Narsis Daftarian; Adriana Lima; Shelby Marozoff; Dami Ojo; Steve D Levasseur; David A L Maberley; Alison Hoens; John Esdaile; Martin Dawes; J Antonio Aviña-Zubieta; Beatrice Adante; Ravinder Dennis Bhui; Suruchi B Bhui; Michael Butler; Lica Chui; Murray Erasmus; Mahyar Etminan; Derek Godinho; Elizabeth Hay; Hussein Hollands; Malvinder Hoonjan; Aaron Joe; Andrew Lukaris; Zaid Mammo; Eduardo Navajas; Kaivon Pakzad-Vaezi; Suren Sanmugasunderam; Kam Shojania Journal: BMJ Open Date: 2022-02-17 Impact factor: 2.692